Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 701–800 of 1,001
Bima, C., Chiloiro, S., Giampietro, A., Gessi, M., Mattogno, P. P., Lauretti, L., Anile, C., Rindi, G., Pontecorvi, A., Marinis, L. D., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.684055 · Cited by 9
Bone microarchitecture impairment in prolactinoma patients assessed by HR-pQCT
Wang, L., Chen, K., Duan, L., Ke, X., Gong, F., Pan, H., Yang, H., Zhu, H., & Xia, W. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06289-4 · Cited by 9
“Current guidelines about prolactinoma suggested that medical treatment should be indicated for those patients with macroadenoma or symptomatic microadenoma, where “symptoms” referred to obvious ones such as galactorrhea, sexual dysfunction, or visual field defect [37, 38].”
BackgroundMahzari, M. M., Alhamlan, K. S., Alhussaini, N., Alkathiri, T. A., Khatir, A. N. A., Alqahtani, A. M., & Masuadi, E. (2022) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2022.334 · Cited by 14
Balen, A. H., Munro, M. G., O’Neill, H. C., Lunenfeld, B., & Fauser, B. C. J. M. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.01.043 · Cited by 10
Yıldız, Y., Hübschmann, O. K., Karaosmanoglu, A. A., Manti, F., Karaca, M., Schwartz, I. V. D., Pons, R. M., López‐Laso, E., Palacios, N. A. J., Porta, F., et al. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12658 · Cited by 11
“4,6,11 12 – 14 Consensus guidelines for the diagnosis and treatment of AADC and BH 4 deficiencies recommend further research on the use of prolactin for diagnosis and monitoring.”
BackgroundInfluentialSurgical Strategies in the Treatment of Giant Pituitary Adenomas
Joshi, K. C., Kolb, B. L., Khalili, B. F., Munich, S. A., & Byrne, R. W. (2023) · Operative Neurosurgery · doi:10.1227/ons.0000000000000896 · Cited by 9
Calandrelli, R., Mattogno, P. P., Chiloiro, S., Gessi, M., D’Apolito, G., Tartaglione, T., Giampietro, A., Bianchi, A., Doglietto, F., Lauretti, L., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14030274 · Cited by 10
“According to the guidelines for each Pit-NET subtype, all patients underwent a complete pre-surgery endocrine evaluation to evaluate their functional status and pituitary function before and after surgery [22–27].”
MethodHyperprolactinemia in women: diagnostic approach
Glezer, A., Garmes, H. M., Kasuki, L., Martins, M. R. A., Elias, P. C. L., Nogueira, V. D. S. N., Silva, A. C. J. D. S. R. E., Maciel, G. A. R., Benetti‐Pinto, C. L., & Nácul, A. P. (2024) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2024fps04 · Cited by 9
“(5) This HPRL may be the result of a pituitary adenoma cosecreting PRL and growth hormone (GH), (14) as well as the compression of the pituitary stalk.”
BackgroundInfluentialClinical aggression of prolactinomas: correlations with invasion and recurrence.
Popescu, M., Ionescu, E. M., Iovănescu, L., Cotoi, B. V., Popescu, A., Gănescu, A., Glodeanu, A. D., Geormăneanu, C., Moraru, A., & Pătraşcu, A. (2013) · PubMed · Cited by 9
Şendur, S. N., Aktöz, F., Usubutün, A., Tuncer, Z. S., & Erbas, T. A. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1587596 · Cited by 9
“Hyperprolactinaemia has various physiological, pathological and pharmacological causes (Melmed et al. 2011).”
BackgroundCauses and Metabolic Consequences of Gynecomastia in Adult Patients
Robeva, R. N., Elenkova, A. P., & Zacharieva, S. (2019) · International Journal of Endocrinology · doi:10.1155/2019/6718761 · Cited by 11
“In case of persistent hyperprolactinemia, the diagnostic approach was focused on exclusion of secondary causes such as medication or nutritional supplements, hypothyroidism, liver or kidney dysfunction, other stress factors, and pituitary mass (MRT) [16, 17].”
Prolactin Reduces Hippocampal Parvalbumin and GABAA Receptor Expression in Female Mice
Mellado, S., Moreno-Ruiz, B., Expósito, S., Fernández, M., & Martín, E. D. (2021) · Neuroendocrinology · doi:10.1159/000520279 · Cited by 10
Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review
Cooper, O. B., Bonert, V. S., Liu, N., & Mamelak, A. N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.725014 · Cited by 9
“5 mg a week, and PRL normalization has been reported with doses as high as 11 mg a week (5, 6).”
BackgroundHigh-Risk Pregnancy: Management Options
Wildschut, H. I. J., Duvekot, J. J., Cook, J. R., Bacchus, L. J., Bewley, S., Creighton, S., Dear, J., Williams, D., Kilby, M. D., Crouch, N. S., et al. (2017) · Cambridge University Press eBooks · doi:10.1017/9781108349185 · Cited by 11
Cai, X., Zhu, J., Yang, J., Tang, C., Cong, Z., & Ma, C. (2022) · Chinese Neurosurgical Journal · doi:10.1186/s41016-022-00277-1 · Cited by 10
“Discussion DAs are the preferred choice in the current guideline, and they are used for treating symptomatic microprolactinomas and macroprolactinomas [157].”
BackgroundInfluentialExtra-Pseudocapsular Transsphenoidal Surgery for Microprolactinoma in Women
Chen, J., Guo, X., Miao, Z., Zhang, Z., Liu, S., Wan, X., Shu, K., Yang, Y., & Lei, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133920 · Cited by 9
“Currently, dopamine agonists (DAs) are highly effective in achieving the goals to normalize prolactin and ameliorate the symptoms of hyperprolactinemia [3,4].”
BackgroundMetabolic effects of dopamine-agonists treatment among patients with prolactinomas
Kabootari, M., Shirmohammadli, H., Golgiri, F., Mosalamiaghili, S., Khajavi, A., & Akbari, H. (2022) · Endocrine · doi:10.1007/s12020-022-03238-x · Cited by 9
Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?
Williams, T. A., Dietz, A., Theodoropoulou, M., Riester, A., Fischer, E., Burrello, J., Treitl, M., Geyer, L. L., Veglio, F., Bidlingmaier, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2422 · Cited by 9
Störmann, S., & Schopohl, J. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.875529 · Cited by 10
“Temozolomide has proven useful in several cases of prolactinomas [181-183] and has therefore been incorporated into current guidelines [184].”
BackgroundSharaibi, O. J., Ogundipe, O. T., Afolayan, A. J., & Aworinde, D. O. (2014) · Journal of Medicinal Plants Research · doi:10.5897/jmpr2014.5501 · Cited by 9
Guaraldi, F., Gori, D., Beccuti, G., Prencipe, N., Giordano, R., Mints, Y. Y., Giacomo, V. S. D., Berton, A. M., Lorente, M., Gasco, V., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0476-y · Cited by 9
Kabiri, M., Kamalinejad, M., Bioos, S., Shariat, M., & Sohrabvand, F. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100758 · Cited by 9
Nass, R. M., & Evans, W. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00020-2 · Cited by 11
Binart, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00005-2 · Cited by 12
Use of Antipsychotics During Pregnancy
Wisner, K. L., Jeong, H., & Chambers, C. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1538 · Cited by 9
Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
Han, C.-Y., Ye, X., Lu, J.-P., Jin, H., Xu, W., Wang, P., & Zhang, M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s410349 · Cited by 8
Sardana, K., Muddebihal, A., Sehrawat, M., Bansal, P., & Khurana, A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2299400 · Cited by 13
Advancement in perioperative management of pituitary adenomas—Current concepts and best practices
Shafiq, I., Williams, Z. R., & Vates, G. E. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13427 · Cited by 8
van Trigt, V. R., Bakker, L. E. H., Lu, H., Pelsma, I. C. M., Verstegen, M. J. T., van Furth, W. R., Arias‐Bouda, L. M. P., & Biermasz, N. R. (2024) · Pituitary · doi:10.1007/s11102-024-01430-y · Cited by 8
Visual morbidity in macroprolactinoma: A retrospective cohort study
Rudman, Y., Duskin‐Bitan, H., Masri‐Iraqi, H., Akirov, A., & Shimon, I. (2024) · Clinical Endocrinology · doi:10.1111/cen.15120 · Cited by 9
Cera, N., Pinto, J., & Pignatelli, D. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09912-x · Cited by 9
Medical treatment prior to micro-TESE
Dasgupta, S., Le, T. V., Rambhatla, A., Shah, R. S., & Agarwal, A. K. (2024) · Asian Journal of Andrology · doi:10.4103/aja202492 · Cited by 11
“60 For cabergoline, a weekly dosage of 0.5–4.5 mg is recommended, and the suggested dosage for bromocriptine is 1–30 mg per day until hyperprolactinemia is corrected.”
InfluentialRudman, Y., Simon, N., Shimon, R., Drozdinsky, G., Markus, E., Duskin‐Bitan, H., Masri‐Iraqi, H., Tsvetov, G., Akirov, A., & Shimon, I. (2025) · Endocrine · doi:10.1007/s12020-025-04215-w · Cited by 8
Clinical management of difficult to treat macroprolactinomas
Sahakian, N., Castinetti, F., Dufour, H., Graillon, T., Romanet, P., Barlier, A., Brue, T. C., & Cuny, T. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1596024 · Cited by 8
“In conclusion, CAB is usually the first-line DA to be proposed with a side effects profile similar to those reported for the other DAs, but generally less frequent, less severe, and of shorter duration [37].”
BackgroundBinge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report
Castro, A. C. C. E., de Araujo, A. A., Botelho, M. C., Nascimento, J. B., de Souza, R. M., Gadelha, M. R., Nardi, A. E., & Violante, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.844718 · Cited by 8
Neuropsychological Alterations of Prolactinomas’ Cognitive Flexibility in Task Switching
Cao, C., Wen, W., Chen, A., Wang, S., Xu, G., Niu, C., & Song, J. (2023) · Brain Sciences · doi:10.3390/brainsci13010082 · Cited by 9
Deep learning based identification of pituitary adenoma on surgical endoscopic images: a pilot study
Fuse, Y., Takeuchi, K., Hashimoto, N., Nagata, Y., Takagi, Y., Nagatani, T., Takeuchi, I., & Saito, R. (2023) · Neurosurgical Review · doi:10.1007/s10143-023-02196-w · Cited by 9
Şenoymak, M. C., ERBATUR, N. H., Şenoymak, İ., & Fırat, S. N. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040330 · Cited by 9
“Instead, emphasis is placed on regular clinical evaluations and the assessment of visual fields as part of the follow-up regimen for optimal management [14–16].”
BackgroundMethodReference intervals for serum prolactin concentrations: analytical and clinical considerations
Coleman, K., & Saleem, M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09927-4 · Cited by 8
“Medications are most frequent cause of non tumoural hyperprolactinaemia [17] and it is important that the pharmacological increases in prolactin seen with these drugs are recognised by clinicians as failure to do so may lead to inappropriate investigations including pituitary MRI.”
InfluentialYj, C., Gz, S., & Wang, Z. (2016) · PubMed · Cited by 8
Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels
Livshits, A., Kravarusic, J., Chuang, E., & Molitch, M. E. (2016) · Pituitary · doi:10.1007/s11102-016-0752-z · Cited by 8
Serum prolactin overestimation and risk of misdiagnosis
Sousa, S. M. C. D., Saleem, M., Rankin, W. A., & Torpy, D. J. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.65 · Cited by 8
Surgical management considerations in cystic prolactinomas—a single center case series
Nevzati, E., Chatain, G. P., Carr, S. B., Lillehei, K. O., & Kerr, J. M. (2019) · Endocrine · doi:10.1007/s12020-019-02076-8 · Cited by 8
Benign and malignant tumors of the central nervous system and pregnancy
Eckenstein, M., & Thomas, A. A. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64240-0.00014-3 · Cited by 9
Lukas, R. V., & Mrugała, M. M. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000942 · Cited by 8
Ogunlade, B., Gbotolorun, S. C., & Ogunlade, A. (2020) · Drug and Chemical Toxicology · doi:10.1080/01480545.2020.1850756 · Cited by 8
“Follicle-stimulating hormone (FSH) stimulates oocytes to mature and when the oocyte matures in the ovary, a surge of the luteinizing hormone (LH) secreted by the pituitary gland stimulates the release of the oocyte through the rupture of the follicle, a process called ovulation (Melmed et al. 2011).”
BackgroundIs Idiopathic Mild Hyperprolactinemia a Cardiovascular Risk Factor?
Koca, A. O., Dağdeviren, M., Akkan, T., Keskin, M., Pamuk, N., & Altay, M. (2021) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_178_20 · Cited by 11
Optimization of a Screening Method for Macroprolactinemia
Yang, W., Guo, Z., Zhou, Y., Du, J., Liu, H., Jia, J.-N., Shen, Y., & Chen, Y. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122723 · Cited by 8
Scherer, M., Zerweck, P., Becker, D., Kihm, L., Jesser, J., Beynon, C., & Unterberg, A. W. (2022) · Neurosurgical Review · doi:10.1007/s10143-022-01810-7 · Cited by 8
Resistant prolactinomas: a case series of 26 patients
Eshkoli, T., Fraenkel, M., Zaid, D., Cohen, D., Yoel, U., Tsvetov, G., Gorshtein, A., Goldbart, A., Greenman, Y., & Shimon, I. (2022) · Endocrine · doi:10.1007/s12020-022-03080-1 · Cited by 8
Sellar masses: diagnosis and treatment
Al-Bader, D., Hasan, A., & Behbehani, R. S. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.970580 · Cited by 8
“A diagnosis of prolactinoma is usually confirmed by serum prolactin levels >250 g/L combined with adenoma detection on highresolution and postcontrast gradient echo (GRE) magnetic resonance (MR) imaging (16).”
BackgroundWexler, T., & Page‐Wilson, G. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15660 · Cited by 13
“been advanced in the literature, including failure to reduce prolactin levels sufficiently to achieve ovulation, failure to reduce tumour size by 50% and/or failure to normalize prolactin levels on maximally tolerated doses.(40,61) Based on the latter definition, approximately 10% of”
BackgroundInfluentialFemale infertility and endocrinological diseases
Özel Medice Hastanesi, K. H. V. D. K., & Boyar, H. İ. (2013) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/diclemedj.0921.2013.04.0363 · Cited by 8
“Prolaktin seviyesini artıran diğer durumlar, gebelik ve emzirme sırasında görülen fizyolojik artış, stres veya ilaç kullanımı olabilir [10].”
Prolactinomas: diagnosis and treatment
Nassiri, F., Cusimano, M. D., Scheithauer, B. W., Rotondo, F., Fazio, A., Syro, L. V., Kovács, K., & Lloyd, R. V. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.4 · Cited by 8
Radiological Growth Patterns of Prolactinomas and Nonfunctioning Adenomas
Imran, S. A., Shankar, J., Hebb, A. L. O., Croul, S. E., & Clarke, D. B. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2017.203 · Cited by 8
“PRLomas who, based on recent guidelines, are generally followed during pregnancy through VF testing.(13) Our data suggest that VF testing may not predict tumor growth in the absence of significant superior extension or massive enlargement of the tumor.”
Effective long-term temozolomide rechallenge in a macroprolactinoma
Zampetti, B., Simonetti, G., Attanasio, R., Silvani, A., & Cozzi, R. C. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0092 · Cited by 8
Prolactin Assays and Regulation of Secretion: Animal and Human Data
Binart, N., Young, J., & Chanson, P. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11836-5_3 · Cited by 8
Non-functioning pituitary adenomas and pregnancy: one-center experience and review of the literature
Rosmino, J., Tkatch, J., Paolo, M. V. D., Berner, S. I., Lescano, S., & Guitelman, M. A. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000232 · Cited by 8
“In addition, the Endocrine Society guidelines for the diagnosis and treatment of hyperprolactinemia 2011 suggested that prolactin levels < 94 ng/mL can distinguish between macroprolactinoma and NFPA (28).”
BackgroundOccurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride
Wang, Z., Haizhi, C., Li, J., Xiaocong, F., Jian-hua, L., Liu, J., Lei, L., & Haiying, J. (2021) · Asia-Pacific Psychiatry · doi:10.1111/appy.12469 · Cited by 8
“At the same time, it was noted that patients with hyperprolactinemia caused by drugs without clinical symptoms did not need special treatment (Melmed et al., 2011).”
BackgroundCipriani, S., Todisco, T., Ghiandai, N., Vignozzi, L., Corona, G., Maggi, M., & Rastrelli, G. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01586-5 · Cited by 8
Chen, A., & Burt, M. G. (2017) · Australian Prescriber · doi:10.18773/austprescr.2017.060 · Cited by 8
The influence of hyperprolactinemia on coagulation parameters in females with prolactinomas
Medic-Stojanoska, M., Mitic, G. P., Mitić, I. M., Spasic, D. T., Ćurić, N., Pekić, S., Kovačev-Zavišić, B., & POPOVIC, V. M. (2014) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1406314m · Cited by 8
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Shah, H., Slavin, A., Botvinov, J., O’Malley, G. R., Sarwar, S. A., & Patel, N. V. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.03.135 · Cited by 8
Headache in pituitary adenomas: frequency, characteristics and outcome after treatment
Scaf, C. R., Altoé, A., Ventura, N., Vincent, M. B., Kasuki, L., & Gadelha, M. R. (2025) · Pituitary · doi:10.1007/s11102-025-01504-5 · Cited by 10
Rojhani, E., Rahmati, M., Firouzi, F., Ziaeefar, P., Soudmand, S. A., Azizi, F., Tehrani, F. R., & Behboudi‐Gandevani, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-87783-1 · Cited by 7
A current perspective of pituitary adenoma MRI characteristics: a review
Gruppetta, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2144230 · Cited by 6
Cai, J., Li, L., Shao, T., Sun, M., Wang, W., Xie, P., Wang, X., Yang, Y., Long, Y., Kang, D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115138 · Cited by 8
Novel imaging techniques in refractory pituitary adenomas
MacFarlane, J., Huynh, K. A., Powlson, A., Kolias, A. G., Mannion, R. A. J., Scoffings, D. J., Mendichovszky, I. A., Cheow, H. K., Bashari, W. A., Jones, J. G., et al. (2023) · Pituitary · doi:10.1007/s11102-023-01304-9 · Cited by 7
Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
van Trigt, V. R., Zandbergen, I. M., Pelsma, I. C. M., Bakker, L. E. H., Verstegen, M. J. T., van Furth, W. R., & Biermasz, N. R. (2023) · Pituitary · doi:10.1007/s11102-023-01346-z · Cited by 7
“Our study spans the era during which DAs were considered the cornerstone of prolactinoma treatment, and surgery was not considered standard [3].”
BackgroundResultInfluentialDeng, S.-W., Xu, Q., Jiang, W., Hong, B., Li, B.-H., Sun, D., & Yang, H.-B. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05240-7 · Cited by 7
“The evaluation of increased serum prolactin levels was performed by laboratory examination, and hyperprolactinemia was defined as greater than 25 µg/L [22].”
MethodSexual dysfunction and associated factors in Behçet’s disease: a case–control study
Varkal, G., Türk, İ., Tüzün, Z., Agbuga, O. D., Mete, B., Coşkun, N. S. Ş., Evran, M., & Özbek, S. (2023) · Rheumatology International · doi:10.1007/s00296-023-05470-8 · Cited by 9
“A prolactin level below 30 µg/l was considered normal in both genders [13].”
The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
Dumitriu-Stan, R.-I., Burcea, I. F., Nastase, V. N., Ceauşu, R. A., Dumitrascu, A. S., Cocoşilă, L. C., Bastian, A. E., Zurac, S., Raica, M., & Poiană, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216162 · Cited by 7
“For the patients with GH-and PRL-co-secretion, the biochemical diagnosis of acromegaly was based on the Endocrine Society Clinical Practice Guidelines [15–17].”
Hofbauer, S., Horka, L., Seidenberg, S., Mutten, R. D., Regli, L., Serra, C., Beuschlein, F., & Erlic, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1363939 · Cited by 11
“Medical treatment with dopamine agonists (DA) is the therapy of choice for PRL with humoral response, de fi ned as normoprolactinemia in 68% of cases, tumor shrinkage in 62% of cases and relieving infertility or other symptoms in 53%, respectively (22, 23).”
BackgroundCui, S., Chen, S., Wu, X., & Wang, Q. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1294417 · Cited by 9
“Furthermore, severe depression was observed only in patients receiving DA treatment (Melmed et al., 2011).”
BackgroundEl‐Shimi, B. I., Mohareb, R. M., Ahmed, H. H., Abohashem, R. S., Mahmoud, K. F., & Hanna, D. H. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400480 · Cited by 11
Zang, Q., Liu, Y., He, J., Yue, X., Zhang, R., Wang, R., & Abliz, Z. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.03.004 · Cited by 7
Gupta, P., Tundup, T., Singh, J., Deb, K. S., Verma, R., & Kumar, N. K. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.01.011 · Cited by 7
Tinospora cordifolia attenuates antipsychotic drug induced hyperprolactinemia in Wistar rats
Tiwari, P. K., Dubey, S. K., & Sahu, P. K. (2019) · Asian Pacific Journal of Reproduction · doi:10.4103/2305-0500.259171 · Cited by 8
“Similarly, cabergoline is another drug of preference for the treatment of hyperprolactinemia[10-12].”
BackgroundBody self-image disturbances in women with prolactinoma
Pereira, H. S., Naliato, E. C. O., Moraes, A. B., Gadelha, M. R., Neto, L. V., de Almeida, R. M. V. R., Nardi, A. E., & Violante, A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0325 · Cited by 9
Macroprolactinemia in patients with hyperprolactinemia: an experience from a single tertiary center
Chutpiboonwat, P., Yenpinyosuk, K., Sridama, V., Kunjan, S., Klaimukh, K., & Snabboon, T. (2020) · Pan African Medical Journal · doi:10.11604/pamj.2020.36.8.22923 · Cited by 7
“Currently, The Endocrine Society guidelines recommend screening for macroprolactinemia in all asymptomatic patients with elevated PRL levels [5].”
BackgroundMethodWierman, M. E. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.12.003 · Cited by 8
Magnetic resonance imaging of the hypothalamo–pituitary region
Perosevic, M., Jones, P. S., & Tritos, N. A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819975-6.00004-2 · Cited by 12
Altered Connectivity of the Frontoparietal Network During Attention Processing in Prolactinomas
Cao, C., Wang, Y., Liu, J., Chen, A., Lu, J., Xu, G., & Song, J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.638851 · Cited by 7
“Patients were included if (1) a prolactin-secreting pituitary tumor was discovered (33, 34), (2) they had never undergone a craniotomy or received radiation therapy, (3) they were able to fulfill ERP examinations, and (4) their age ranged from 20 to 50 years old, with all of them completing at least secondary school e…”
BackgroundCurrent pharmacotherapy and future directions for neuroendocrine causes of female infertility
Koysombat, K., Abbara, A., & Dhillo, W. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2064217 · Cited by 10
“(median 78%; range 40–100%) and achieving pregnancy (53%; 10–100%) [25].”
BackgroundInfluentialCross-reactivity in assays for prolactin and optimum screening policy for macroprolactinaemia
Smith, T. P., Kelly, S., & Fahie‐Wilson, M. N. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0459 · Cited by 7
Jurek, A., Krzesiński, P., Gielerak, G. G., Witek, P., Zieliński, G., Kazimierczak, A., Wierzbowski, R., Banak, M., & Uziębło‐Życzkowska, B. (2022) · Nutrients · doi:10.3390/nu14245369 · Cited by 7
Surgical Management of Giant Prolactinomas: A Descriptive Study
Lundholm, M. D., Yogi-Morren, D., Pantalone, K. M., Recinos, P. F., Kshettry, V. R., & Rao, P. P. R. (2023) · International Journal of Endocrinology · doi:10.1155/2023/1990259 · Cited by 7
“For patients with malignant prolactinoma, temozolomide is another medication to reduce prolactin levels [27].”
BackgroundNelson, L. M., Spencer, H., Hijane, K., Thinuan, P., Nelson, C. W., Vincent, A. J., Gordon, C. M., Plant, T. M., & Fazeli, P. K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1227253 · Cited by 13
“In some cases, the risk of withdrawing medications such as antipsychotics may exceed the benefits of restoring ovarian function and this should only be done in coordination with the provider prescribing the medication(s) (93).”
BackgroundInfluentialBenetti‐Pinto, C. L., Nácul, A. P., Silva, A. C. J. D. S. R. E., Maciel, G. A. R., Nogueira, V. D. S. N., Elias, P. C. L., Martins, M. R. A., Kasuki, L., Garmes, H. M., & Glezer, A. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0504 · Cited by 7
Hyperthyroidism and Hyperprolactinemia: Is There any Association?
Sanjari, M., Safi, Z., & Tahroodi, K. M. (2016) · Endocrine Practice · doi:10.4158/ep161293.or · Cited by 7
Long-term outcome of macroprolactinomas
Képénékian, L., Cébula, H., Castinetti, F., Graillon, T., Brue, T. C., & Goichot, B. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.07.004 · Cited by 6
Li, N., & Jiang, Z. (2016) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2016.11.020 · Cited by 7
Secondary amenorrhea: Diagnostic approach and treatment considerations
Pereira, K. C., & Brown, A. J. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000520832.14406.76 · Cited by 11
“When prolactin levels are elevated (2 to 10 times normal), this usually indicates a prolactin-lactotroph-secreting pituitary adenoma.(9)”
BackgroundKim, Y., Seo, G. H., Kim, Y.-M., Choi, J., & Yoo, H. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0268 · Cited by 7
Chiloiro, S., Giampietro, A., Bianchi, A., & Marinis, L. D. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.02.006 · Cited by 8
Prolactin, prolactin disorders, and dopamine agonists during pregnancy
Levin, G., & Rottenstreich, A. (2018) · HORMONES · doi:10.1007/s42000-018-0071-z · Cited by 9
Management of prolactinoma: a survey of endocrinologists in China
Ji, L., Yi, N., Zhang, Q., Zhang, S., Liu, X., Shi, H., & Lü, B. (2018) · Endocrine Connections · doi:10.1530/ec-18-0250 · Cited by 7
Tavakol, S., Hasan, A., Wedemeyer, M. A., Bakhsheshian, J., Liu, C. J., Shiroishi, M. S., Mathew, A. J., Carmichael, J. D., & Zada, G. (2019) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0039-1677678 · Cited by 7
Zhang, W., Du, Q., Bian, P., Xiao, Z., Wang, X., Feng, Y., Hou, F., Zhu, Z., Gao, N., Zhu, D., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1113 · Cited by 7
“Ergot-derived dopamine receptor agonists (DAs), including bromocryptine (BRC) and cabergoline (CAB), are the main therapeutic agents for prolactinomas (4,5).”
Background
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.